Of note, ATP13A4 underwent amplification in over 10% of patients with ovarian cancer, cervical cancer, head and neck cancer, endometrial cancer, uterine endometrioid carcinoma, bladder cancer, melanoma, lung cancer and breast cancer. Here, ATP13A4 is linked to urinary bladder cancer.